"The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
ALL is the most common type of pediatric "...
Arzerra Patient Information including How Should I Take
In this Article
- What is ofatumumab (Arzerra)?
- What are the possible side effects of ofatumumab (Arzerra)?
- What is the most important information I should know about ofatumumab (Arzerra)?
- What should I discuss with my healthcare provider before receiving ofatumumab (Arzerra)?
- How is ofatumumab given (Arzerra)?
- What happens if I miss a dose (Arzerra)?
- What happens if I overdose (Arzerra)?
- What should I avoid while receiving ofatumumab (Arzerra)?
- What other drugs will affect ofatumumab (Arzerra)?
- Where can I get more information?
What should I discuss with my healthcare provider before receiving ofatumumab (Arzerra)?
Ofatumumab increases the risk of a serious viral infection of the brain that can lead to disability or death. This risk is higher if you have a weak immune system or are receiving certain medicines.
If you have any of these other conditions, you may need a dose adjustment or special tests to safely use this medication:
- severe COPD (chronic obstructive pulmonary disease);
FDA pregnancy category C. It is not known whether ofatumumab is harmful to an unborn baby. Before taking this medication, tell your doctor if you are pregnant or plan to become pregnant during treatment.
It is not known whether ofatumumab passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.
How is ofatumumab given (Arzerra)?
Ofatumumab is given as an injection through a needle placed into a vein. You will receive this injection in a clinic or hospital setting. The medicine must be given slowly through an IV infusion, and one dose can take up to several hours to complete.
Ofatumumab is usually given in a series of 12 doses. The first 8 doses are given 1 week apart. The last 4 doses are given 4 weeks apart. Your dosing schedule may be different. Follow your doctor's instructions.
You will be given other IV or oral (by mouth) medications to prevent certain side effects of ofatumumab. You may need to start using these medications up to 2 hours before the start of your ofatumumab infusion.
To be sure this medication is not causing harmful effects, your blood cells, kidney function, and liver function may need to be tested on a regular basis. Ofatumumab can have long-lasting effects on your body. Do not miss any follow-up visits to your doctor for blood or urine tests.
If you have hepatitis B you may develop liver symptoms after you stop taking this medication, even months after stopping. Your doctor may want to check your liver function at regular visits for several months after you stop using ofatumumab. Do not miss any scheduled appointments.
Additional Arzerra Information
- Arzerra Drug Interactions Center: ofatumumab iv
- Arzerra Side Effects Center
- Arzerra Overview including Precautions
- Arzerra FDA Approved Prescribing Information including Dosage
Arzerra - User Reviews
Arzerra User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.